Shyam Sankar | All In Summary

Participants: David Friedberg (host), Shyam Sankar (Palantir), Trae Stephens (Anduril)

1. Key Themes

America's Defense Industrial Base Has Been Hollowed Out — and the Consequences Are Severe

The US has undergone a dramatic structural shift in how defense hardware gets made. What was once a dual-purpose industrial economy has become almost entirely dependent on pure-play defense specialists — a fragile and strategically dangerous configuration.

"When the Berlin Wall still stood in 1989, only 6% of spending on major weapons systems went to pure play defense specialists. 94% of it went to what I call dual purpose companies... That figure today is 86% goes to defense specialists." — Shyam Sankar 00:07:45

"When Ukraine went through 10 years of production in 10 weeks of fighting, that probably should have been a five alarm fire that we got the fundamental calculus on deterrence wrong. We thought the stockpile was going to deter our adversaries. It was always the factory." — Shyam Sankar 00:08:39

The New Defense Paradigm: Software-Defined, Hardware-Enabled

The core thesis of companies like Anduril is to invert the traditional defense model — build products first with private R&D capital, then sell the output, rather than waiting for government specs. This is a fundamentally different and more innovation-friendly business model.

"The government doesn't know how to think about the value that's created by software... For hardware, they know there's a bill of materials... they can kind of go through a spreadsheet and say, okay, I know how much it costs for you to build this." — Trae Stephens 00:23:18

"I felt like someone should be building a next-gen prime that builds hardware, but it's software-defined and hardware-enabled rather than being hardware-defined and software-enabled." — Trae Stephens 00:25:13

Autonomous Systems and Attritable Mass Will Define Future Warfare

The high-low cost mix in defense spending must shift dramatically. The era of exclusively expensive, exquisite platforms is ending. Cheap, autonomous, expendable systems are the future — and the US is dangerously behind on producing them at scale.

"You can't keep shooting $2 million interceptors at $20,000 drones and have that math work very long." — Shyam Sankar 00:09:51

"The high low mix is going to have to shift massively. I mean, this is just like clearly evident in Ukraine. It's clearly evident in Iran." — Trae Stephens 00:46:52

2. Contrarian Perspectives

Abstaining from Defense Work Is Not a Morally Neutral Decision

Most tech workers who protest defense contracts believe they are taking the ethical high ground. Stephens argues the opposite — abstention is itself a moral choice, and often an indefensible one.

"I don't think abstention from participating in the building of technology for national security is a morally neutral decision. You are making a moral decision when you decide to abstain." — Trae Stephens 00:50:21

The Military Industrial Complex Is Actually a Bad Business — Not a Profit Machine

The popular narrative is that defense contractors profit enormously from war. The reality is the opposite: defense is structurally underprofitable, which is precisely why innovation has stagnated.

"The cynical view that like you have the military industrial complex and they're just in it to make money. Well, it's kind of a crappy business. Like, you know, these companies trade at like less than two times revenue." — Shyam Sankar 00:44:03

Letting Tech Vendors Override Democratic Policy Decisions Is Itself a Form of Tyranny

The Anthropic/Maven situation brought this to a head. Sankar argues that tech companies restricting how democratically authorized institutions use their tools are engaging in unaccountable power — "tyranny by tech bro."

"If you are salami slicing the policy, that's actually tyranny by tech bro. You know, a small number of people are constraining the maneuver space of a democracy with no accountability to the populace." — Shyam Sankar 00:52:11

Anti-Defense Protests in Silicon Valley Are Partially Foreign-Funded Operations

This is widely dismissed as conspiracy thinking, but Sankar names it directly with historical and present-day backing.

"The Soviets spent $7 billion in 2026 funding the peace movement, the anti-war protests... In the present day, certainly we see it against Palantir where there's CCP money flowing to organizations that are protesting us for various domestic issues here." — Shyam Sankar 01:00:02

Munitions Should Be Treated as Consumables, Not Capital Assets

This reframe of how the DoD thinks about weapons procurement is deeply counterintuitive within the existing system but is the key to unlocking industrial base regeneration.

"Reimagining munitions and drones as consumables... they're things that you, at the time of ordering them, you already have an exercise test plan where you plan to expend them, which means that you're going to have to replenish them, which means there's a demand signal to industry to keep going." — Shyam Sankar 00:36:10

3. Companies Identified

Anduril Industries Next-generation defense prime building autonomous hardware systems (drones, interceptors, autonomous submarines) with a product-led, private R&D model. Currently building Arsenal One, a 5M sq ft manufacturing campus in Columbus, Ohio. Reportedly raising at $60B valuation, recently won a $20B Army contract.

"We just opened Arsenal yesterday to start producing Furies. And, you know, looking out over the next 18 months, we're not taking our foot off the gas." — Trae Stephens 00:44:48

Palantir Technologies Data integration and analytics platform serving both government and commercial clients. Currently valued at ~$400B. Described as "Excel with cell-by-cell security" — a platform for lawful data analysis, not data collection.

"We don't collect data. We don't have any data. It'd be like accusing Excel of being a surveillance tool... this is a way of bringing your own data that you have lawful authorities to collect together to make decisions." — Shyam Sankar 00:51:05

SpaceX Cited as the only comparable example of at-scale new manufacturing built in America this century, and as a model for how cost-plus government contracting destroys price-performance innovation.

"Starship heavy reuse will be under 20 bucks a kilogram... there's no way that you will achieve that vision if you're in a cost plus world." — Shyam Sankar 00:27:02

Expanse (formerly KDM, acquired by Palo Alto Networks) The one GovTech investment Founders Fund made during Trae Stephens' years of searching through hundreds of companies — a signal of how barren the defense tech landscape was before Anduril's founding.

"We ended up making one investment in KDM, which was renamed Expanse and acquired by Palo Alto Networks. But otherwise, that was it. There was nothing else." — Trae Stephens 00:24:43

4. People Identified

Shyam Sankar CTO of Palantir. Former early employee (#13 era), built the government business. Author of a new book on defense innovation ("Mobilize"). One of the most articulate public voices on defense industrial policy, autonomous systems ethics, and the strategic importance of re-industrialization.

"Every one of these innovations is kind of an act of heresy. There's a founder-like figure who is so committed pathologically to a different heretical concept." — Shyam Sankar 00:16:23

Trae Stephens Co-founder of Anduril. Former Palantir employee, then partner at Founders Fund where he searched the GovTech landscape and found nothing worth investing in — which led him to found Anduril. Brings rare combination of IC/intelligence community background, venture experience, and operator insight.

"I felt like I understood pretty well, which was GovTech... I met with hundreds of companies in the first three years... we didn't miss anything. There was just nothing worth investing in." — Trae Stephens 00:24:43

Kelly Johnson (Skunk Works founder) Historical figure cited as the archetype of what defense innovation requires: a founder-hero who actively defended his program from bureaucratic interference. Built 41 airframes including the SR-71 and U-2.

"One of his rules was he had to play defense to keep the government bureaucrats out of his program." — Shyam Sankar 00:39:39

Colonel Drew Cukor Described as the true founder of Project Maven (DoD's AI targeting initiative). Called out as one of Sankar's "heretics and heroes" — and notably, was weaponized against via inspector general complaints as a way to suppress defense AI innovation.

"Colonel Drew Cukor, who invented Maven, the founder of Maven, really... people would file complaints claiming that he was hiding illegal immigrants in his basement." — Shyam Sankar 00:55:42

Bob Noyce (Fairchild/Intel co-founder) Cited as the historical model for how private R&D independence — refusing to let the government define your roadmap even when they're your only customer — leads to breakthroughs that eventually serve national security far better.

"He was so maniacally committed to a future that semiconductors would be in everything that he never let more than 4% of his R&D be paid for by the government." — Shyam Sankar 00:26:23

5. Operating Insights

Deliberately Compress Your Revenue Multiple With Each Funding Round

Anduril has made it a discipline to raise each successive round at a lower revenue multiple than the prior one — not because investors wouldn't pay more, but because the discipline prepares the company for a credible IPO and avoids the "playing chicken" trap with inflated expectations.

"We never want to go and raise the next round at a higher revenue multiple than the prior round. And even the series H that you mentioned before is down pretty significantly from the series G. And we're not doing that because investors wouldn't be willing to pay higher multiples. We're doing that because I believe the discipline is really, really important, especially heading into a medium term IPO." — Trae Stephens 00:29:58

Build Your Factory Like a Contract Manufacturer, Not a Single-Product Line

Anduril's Arsenal One is deliberately designed for modularity — the ability to pivot production between Furies, Roadrunners, and Barracudas on demand. The lesson from Ukraine's Stinger/Javelin shortage is that single-product lines become liabilities in actual conflict.

"We want to be able to pivot on a dime into ramping up production of Roadrunners if we need Roadrunners, or ramping up production of Barracudas if we need Barracudas... like a contract manufacturer." — Trae Stephens 00:13:39

Tell Your Story Proactively — Silence Is Not a Neutral Strategy

Stephens' one explicit lesson from Palantir that he applied at Anduril: the reticence to communicate publicly created a vacuum that enemies (foreign and domestic) filled with damaging narratives. Proactive comms is a strategic asset.

"The one lesson that I learned that we didn't implement at Palantir is we're going to go out there and tell our story. And I think that's worked for us incredibly well." — Trae Stephens 00:05:43

6. Overlooked Insights

Pharmaceuticals Are the Next DJI — America Is Sleepwalking Into a Critical Vulnerability

This was mentioned briefly and then dropped, but it may be the most actionable near-term investment and policy insight in the entire conversation. 80% of active pharmaceutical ingredients (APIs) for generic drugs are made in China. The strategic implication — that China could weaponize medicine access during a conflict — is profound and almost entirely underdiscussed in the tech/defense investment community.

"80% of APIs for generic drugs are produced by China. What do you think the American people are going to think when they have to choose between defending the free world, defending American sovereignty, and their five-year-old dying of an ear infection that we would have thought of as trivially curable?" — Shyam Sankar 00:32:47

This is a direct analog to what happened with semiconductors and drones: America innovated, offshored production for cost efficiency, lost the manufacturing base, and is now in a strategically compromised position. Domestic pharmaceutical API manufacturing is wide open for investment and carries both strong policy tailwinds (reshoring) and a compelling national security thesis.

50% of All New Clinical Trials Are Now Happening in China

Sankar dropped this statistic almost parenthetically, but it signals something larger: China is not just winning on manufacturing — it is accumulating the data, institutional knowledge, and regulatory pathway dominance in next-generation drug development. This has profound implications for biotech investment strategy and where the frontier of pharmaceutical innovation will be located in 10 years.

"There's a reason 50% of all clinical trials, new clinical trials, are happening in China and not in the US." — Shyam Sankar 00:33:17